Kallikrein gene 'knock-down' by small interfering RNA transfection induces a profibrotic phenotype in rat mesangial cells

Journal of Hypertension

Volumn 26, Issue 1, 2008, Pages 93-101

  Pawluczyk, Izabella Z A ^a,b   Tan, Eddie K C ^b   Lodwick, David ^a   Harris, Kevin P G ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Fibrosis; Kallikrein; Mesangial cells

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; FIBRONECTIN; GELATIN; GELATINASE A; KALLIKREIN; KININ; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTEINASE; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FIBROGENESIS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENOTYPE; KIDNEY FIBROSIS; KNOCKOUT GENE; MALE; MESANGIUM CELL; MOLECULAR WEIGHT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; RENAL PROTECTION; SUPERNATANT; URINE; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LDL-RECEPTOR RELATED PROTEIN 1; MALE; MATRIX METALLOPROTEINASE 2; MESANGIAL CELLS; PHENOTYPE; RATS; RATS, WISTAR; RECEPTOR, BRADYKININ B2; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE KALLIKREINS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 37349102343     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f0ca68     Document Type: Article

References (37)

1. Clements JA. The glandular kallikrein family of enzymes: tissue specific expression and hormonal regulation. Endocr Rev 1989; 10: 393-419.
2. Wang DZ, Song Q, Chen LM, Chao L, Chao J. Expression and cellular localisation of tissue kallikrein-kinin systems in human adrenal gland. Am J Physiol 1996; 272:F709-F716.
3. Wolf WC, Harley RA, Sleuce D, Chao L, Chao J. Localisation and expression of tissue kallikrein-kinin and kallistatin in human blood vessels. J Histochem Cytochem 1999; 47:221-228.
4. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins, kallikreins, kininogens, and kinases. Pharmacol Rev 1992; 44:1-80.
5. Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, et al. Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2 receptor-mediated event. Nephron 1999; 81:183-193.
6. Wang DZ, Chao L, Chao J. Hypotension in transgenic mice over-expressing human bradykinin B2 receptor. Hypertension 1997; 29:488-493.
7. Margolius HS, Horowitz DZ, Pisano JJ, Keiser HR. Urinary kallikrein excretion in hypertensive man: relationships to sodium intake and sodium retaining steroids. Circ Res 1974; 35:820-825.
8. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 123:3-8.
9. Lin L, Zhang JJ, Chao L, Chao J. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 1997; 8:1753-1761.
10. Chao J, Zhang JJ, Lin KF, Chao L. Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 1998; 9:21-31.
11. Yamaha K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31:1104-1110.
12. Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, et al. Long term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 1994; 24:770-877.
13. Pawluczyk IZA, Patel SR, Harris KPG. The role of bradykinin in the antifibrotic effects of perindoprilat on human mesangial cells. Kidney Int 2004; 65:1240-1251.
14. Pawluczyk IZA, Patel SR, Harris KPG. The role of the alpha-1 adrenoceptor in modulating human mesangial cell matrix production. Nephrol Dial Transpl 2006; 21:2417-2424.
15. Pawluczyk IZA, Patel SR, Harris KPG. Pharmacological enhancement of the kallikrein-kinin system promotes antifibrotic responses in human mesangial cells. Cell Physiol Biochem 2006; 18:327-336.
16. Yayama K, Nagaoka M, Takano M, Okamoto H. Expression of kininogen, kallikrein, and kinin receptor genes by rat cardiomyocytes. Biochim Biophys Acta 2000; 1495:69-77.
17. Martin J, Knowlden J, Davies M, Williams JD. Identification and independent regulation of human mesangial cell metalloproteinases. Kidney Int 1994; 46:877-885.
18. Pawluczyk IZA, Harris KPG. Macrophages promote pro-sclerotic responses in cultured rat mesangial cells. A mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol 1997; 8:1525-1536.
19. Xia CF, Bledsoe G, Chao L, Chao J. Kallikrein gene transfer reduces renal fibrosis, hypertrophy and proliferation in DOCA-salt hypertensive rats. Am J Renal Physiol 2005; 289:F622-F631.
20. Markwardt F, Klocking HP. Studies on the release of plasminogen activator. Thromb Res 1976; 8:217-223.
21. Emeis JJ, Tranquille N. The role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38 (Suppl):285-291.
22. Herz J, Strickland DK. LRP: a multifunctional scavenger and signalling receptor. J Clin Invest 2001; 108:779-784.
23. Pawluczyk IZA, Patel SR, Harris KPG. The ACE inhibitor perindoprilat modulates the activity of the low density lipoprotein receptor-related protein (LRP) in human mesangial cells [abstract]. J Am Soc Nephrol 2006; 17:251A.
24. Frey EK. Kreislaufhormon und innere secretion. Munch Med Wschr 1929; 76:1951-1952.
25. Raab WP. Enzymes and isoenzymes in urine. Curr Probl Clin Biochem 1968; 2:17-83.
26. Frey EK, Kraut H, Werle E, Vogel R, Zickgraf-Rudel G, Trautschold I. Das kallikrein-kinin system und seine inhibitorem. Stuttgart: F Enke-Verlag; 1968.
27. Goud HD, Oza NB, Mitsialis SA, Levinsky NG. Regulation of renal rK1 kallikrein in spontaneously hypertensive rats. Ren Physiol Biochem 1993; 16:125-130.
28. Van Leewen BH, Grinblat SM, Johnson CI. Tissue specific control of glandular kallikreins. Am J Physiol (Renal Fluid Electrolyte Physiol) 1984; 247:F760-F764.
29. Tomiya N, Yamaguchi T, Awaya J, Kurono M, Endo S, Arata Y, et al. Structural analysis of asparagines-linked oligosaccharides of porcine pancreatic kallikrein. Biochemistry 1988; 27:7146-7154.
30. Cumming AD, Walsh T, Wojtacha D, Fleming S, Thomson D, Jenjins DA. Expression of tissue kallikrein in human kidney. Clin Sci 1994; 87:5-11.
31. Takahashi S, Irie A, Miyake Y. Primary structure of human urinary prokallikrein. J Biochem 1988; 104:22-29.
32. Zhang JJ, Bledsoe G, Kato K, Chao L, Chao J. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 2004; 66:722-732.
33. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185:963-968.
34. Salicioni AM, Mizelle KS, Loukinova E, Mikhailenko I, Strickland DK, Gonias SL. The low density lipoprotein receptor-related protein mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces. J Biol Chem 2002; 277:16160-16166.
35. Ito K, Chen J, Khodadadian JJ, Seshan SV, Eaton C, Zhao X, et al. Liposome-mediated transfer of nitric oxide synthase gene improves renal function in ureteral obstruction in rats. Kidney Int 2004; 66:1365-1375.
36. Datta PK, Sharma M, Duann P, Lianos EA. Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury. Exp Biol Med 2006; 231:576-584.
37. Kumar U, Chen J, Sapoznikhov V, Canteros G, White BH, Sidhu A. Over expression of inducible nitric oxide synthase in the kidney of the spontaneously hypertensive rat. Clin Exp Hypertens 2005; 27:17-31.